In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis. The primary outcome were major kidney disease events, onset of kidney failure, a 50% reduction of eGFR from baseline or death from kidney related or cardiovascular causes.
Findings showed that the risk of a primary outcome event was 24% lower in the patients who had received semaglutide as compared to those who had received placebo, with similar findings from the kidney-specific outcomes. Confirmatory secondary endpoints also favoured semaglutide over placebo.
Questions:
-What is the importance of the FLOW trial?
-What was the patient population and study design?
-What are the key findings and safety outcomes?
-What are the implications of these findings on clinical practice?
-What are the next steps?
Recorded Remotely from Kensington, 2024.
Visit Radcliffe Cardiology:
Visit Radcliffe Vascular:
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook:
Follow us on X:
Музыка
Фильмы
ТВ Шоу
Категории видео
